Table 2.
Efficacy of first line treatment in 19 patients with stage IV lung adenocarcinoma
Group crizotinib (n = 7) | Group chemotherapy (n = 12) | |
---|---|---|
Case available for evaluation | 6 | 12 |
CR | 0 | 0 |
PR | 5 (83.3%) | 3 (25.0%) |
SD | 1 (16.7%) | 6 (50.0%) |
PD | 0 | 3 (25.0%) |
ORR | 5/6 (83.3%) | 3/12 (25.0%) |
DCR | 6/6 (100.0%) | 9/12 (75.0%) |
Case unavailable for evaluation. | 1 | 0 |
CR, complete response; DCR, disease control rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.